NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses the nuances of immunotherapy related adverse events in melanoma.

Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma.

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.

Marc J. Braunstein, MD, PhD, discusses challenges pertaining to the bone marrow microenvironment in multiple myeloma.

Jeffrey S. Weber, MD, PhD, discusses the phase III EORTC1325/KEYNOTE-054 trial, which looked at adjuvant pembrolizumab in patients with stage III melanoma.

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology.